Margaret Tempero, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-353-7528
PronounsShe/Her/Hers
vCardDownload vCard

Collapse Biography 
Collapse education and training
University of NebraskaM.D.1977School of Medicine
Collapse awards and honors
UCSF2012  - PresRombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
UCSF2000  - 2012Doris and Don Fisher Distinguished Professor in Clinical Research
Journal Nat'l Comprehensive Cancer Network2014  - PresEditor-In-Chief

Collapse Overview 
Collapse overview
Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN. Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section and served as a member and Chair of the NCI Board of Scientific Counselors Subcommittee A. She is a member of the Scientific Steering Committee and Chair of the Clinical and Translational Study Section for the Cancer Prevention & Research Institute of Texas. She is or has been on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board, and the EORTC. She served as a member of the Oncology Drug Advisory Committee for the FDA. She has served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center. She is Chief Emeritus of the Division of Medical Oncology at UCSF. She served as the founding Deputy Director and was later Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center.

Collapse Research 
Collapse research activities and funding
Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
NIH R21CA184429Sep 15, 2014 - Aug 31, 2018
Role: Principal Investigator
Mechanism-Based Evaluations of ErbB-Targeted Agents
NIH U54CA090788Sep 26, 2001 - Dec 31, 2008
Role: Principal Investigator
Cancer Center Support Grant
NIH P30CA082103Aug 5, 1999 - May 31, 2023
Role: Co-Investigator
SPORE IN GASTOINTESTINAL CANCER
NIH P50CA072712Sep 1, 1997 - Jan 31, 2005
Role: Co-Principal Investigator
DEFINING TOXICITY AND BENEFIT FOR RADIOIMMUNOTHERAPY
NIH U01CA058272Sep 30, 1993 - Sep 29, 2000
Role: Principal Investigator
Show more

Collapse ORNG Applications 
Collapse Clinical Trials

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Multi-cancer early detection tests: Attributes for clinical implementation. Cancer Biomark. 2025 Feb; 42(2):18758592241297849. Ebbert JO, Hawk ET, Chambers CV, Tempero MA, Fishman EK, Ravenell JE, Beer TM, Rego SP. PMID: 40171802.
    View in: PubMed   Mentions:    Fields:    
  2. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Ann Surg Oncol. 2024 Jul 27. Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK. PMID: 39068310.
    View in: PubMed   Mentions:    Fields:    
  3. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Ann Surg Oncol. 2024 Sep; 31(9):6147-6156. Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK. PMID: 38879670; PMCID: PMC11300478.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  4. Letter to Santa. J Natl Compr Canc Netw. 2023 12; 21(12):1215. Tempero M. PMID: 38081127.
    View in: PubMed   Mentions:    Fields:    
  5. Giving Thanks. J Natl Compr Canc Netw. 2023 11; 21(11):1109. Tempero M. PMID: 37935094.
    View in: PubMed   Mentions:    Fields:    
  6. It Just Keeps Getting Better! J Natl Compr Canc Netw. 2023 10; 21(10):987. Tempero M. PMID: 37856228.
    View in: PubMed   Mentions:    Fields:    
  7. Understanding Cancer Risk-Genes Matter! J Natl Compr Canc Netw. 2023 09; 21(9):893. Tempero M. PMID: 37673114.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  8. Being Sick Isn't Easy. J Natl Compr Canc Netw. 2023 08; 21(8):785. Tempero M. PMID: 37549910.
    View in: PubMed   Mentions:    Fields:    
  9. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 07; 21(7):753-782. Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. PMID: 37433437.
    View in: PubMed   Mentions: 25     Fields:    Translation:Humans
  10. A Glimpse Into the Future. J Natl Compr Canc Netw. 2023 07; 21(7):687. Tempero M. PMID: 37433438.
    View in: PubMed   Mentions:    Fields:    
  11. "The Times They Are A-Changin' ". J Natl Compr Canc Netw. 2023 06; 21(6):587. Tempero M. PMID: 37308121.
    View in: PubMed   Mentions:    Fields:    
  12. Clinical Trials: Does One Size Really Fit All? J Natl Compr Canc Netw. 2023 05; 21(5):433. Tempero M. PMID: 37156480.
    View in: PubMed   Mentions:    Fields:    
  13. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023 06 01; 41(16):3063-3071. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. PMID: 37075273.
    View in: PubMed   Mentions: 64     Fields:    Translation:Humans
  14. I'm Getting Better at This! J Natl Compr Canc Netw. 2023 04; 21(4):335. Tempero M. PMID: 37015330.
    View in: PubMed   Mentions:    Fields:    
  15. Dying in the Queue and Where Is My Nurse? J Natl Compr Canc Netw. 2023 03; 21(3):231. Tempero M. PMID: 36898364.
    View in: PubMed   Mentions:    Fields:    
  16. Your Words Mean Something! J Natl Compr Canc Netw. 2023 02; 21(2):101. Tempero M. PMID: 36791761.
    View in: PubMed   Mentions:    Fields:    
  17. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. J Immunother Cancer. 2023 01; 11(1). Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J, Sivagnanam S, Cheung A, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Ware C, Bridge M, Vo J, Dragomanovich H, Sudduth-Klinger J, Vaccaro G, Lopez CD, Tempero M, Coussens LM, Fong L. PMID: 36593070; PMCID: PMC9809229.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
  18. Another New Beginning. J Natl Compr Canc Netw. 2023 01; 21(1):1. Tempero M. PMID: 36630896.
    View in: PubMed   Mentions:    Fields:    
  19. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 04 10; 41(11):2007-2019. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M, APACT Investigators. PMID: 36521097; PMCID: PMC10082313.
    View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
  20. Letter to Santa. J Natl Compr Canc Netw. 2022 12; 20(12):1279. Tempero M. PMID: 36509076.
    View in: PubMed   Mentions:    Fields:    
  21. Welcome Aboard! J Natl Compr Canc Netw. 2022 11; 20(11):1189. Tempero M. PMID: 36351337.
    View in: PubMed   Mentions:    Fields:    
  22. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023 01; 34(1):91-100. Seufferlein T, Uhl W, Kornmann M, Algül H, Friess H, König A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. PMID: 36209981.
    View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
  23. We Are Winning This War! J Natl Compr Canc Netw. 2022 10; 20(10):1073. Tempero M. PMID: 36240853.
    View in: PubMed   Mentions:    Fields:    
  24. Together Again! J Natl Compr Canc Netw. 2022 09; 20(9):965. Tempero M. PMID: 36075390.
    View in: PubMed   Mentions:    Fields:    
  25. My Report Card. J Natl Compr Canc Netw. 2022 08; 20(8):853. Tempero M. PMID: 35948030.
    View in: PubMed   Mentions:    Fields:    
  26. Failure Doesn't Feel Good! J Natl Compr Canc Netw. 2022 07; 20(7):737. Tempero M. PMID: 35830894.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  27. I Cannot Afford This! J Natl Compr Canc Netw. 2022 06; 20(6):615. Tempero M. PMID: 35714674.
    View in: PubMed   Mentions:    Fields:    
  28. Out in the World Again. J Natl Compr Canc Netw. 2022 05; 20(5):429. Tempero M. PMID: 35545170.
    View in: PubMed   Mentions:    Fields:    
  29. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas. 2022 04 01; 51(4):302-304. Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH. PMID: 35695740.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCells
  30. It's OK to Share! J Natl Compr Canc Netw. 2022 04; 20(4):317. Tempero M. PMID: 35390764.
    View in: PubMed   Mentions:    Fields:    
  31. Getting Complex Therapies to More People: A Vexing Dilemma. J Natl Compr Canc Netw. 2022 03; 20(3):217. Tempero M. PMID: 35276671.
    View in: PubMed   Mentions:    Fields:    
  32. News About the Tiny Pharmacists Within Us. J Natl Compr Canc Netw. 2022 02; 20(2):99. Tempero M. PMID: 35130496.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  33. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. Am J Clin Oncol. 2022 01 01; 45(1):22-27. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. PMID: 34864778.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  34. Starting Over, Again! J Natl Compr Canc Netw. 2022 01; 20(1):1. Tempero M. PMID: 34991069.
    View in: PubMed   Mentions:    Fields:    
  35. Thank You, Santa! J Natl Compr Canc Netw. 2021 12; 19(12):1365. Tempero M. PMID: 34902827.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  36. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. ESMO Open. 2022 02; 7(1):100339. Sessa C, Cortes J, Conte P, Cardoso F, Choueiri T, Dummer R, Lorusso P, Ottmann O, Ryll B, Mok T, Tempero M, Comis S, Oliva C, Peters S, Tabernero J. PMID: 34953404; PMCID: PMC8608656.
    View in: PubMed   Mentions: 17  Translation:HumansCellsPHPublic Health
  37. Reimagining Professional Meetings: Another Lesson From COVID-19. J Natl Compr Canc Netw. 2021 11; 19(11):1211. Tempero M. PMID: 34781269.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  38. Five Patients and One Important Lesson. J Natl Compr Canc Netw. 2021 10 15; 19(10):1115. Tempero M. PMID: 34666311.
    View in: PubMed   Mentions:    Fields:    
  39. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist. 2021 11; 26(11):e1982-e1991. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. PMID: 34506673; PMCID: PMC8571767.
    View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
  40. Targeting KRAS: Good, But Is It Good Enough? J Natl Compr Canc Netw. 2021 09 20; 19(9):997. Tempero M. PMID: 34551387.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  41. Something to Crow About! J Natl Compr Canc Netw. 2021 08 01; 19(8):881-882. Tempero M. PMID: 34416712.
    View in: PubMed   Mentions:    Fields:    
  42. Pan-Cancer Screening: A Dream or a Nightmare. J Natl Compr Canc Netw. 2021 07 28; 19(7):773. Tempero M. PMID: 34340210.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  43. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 10 15; 27(20):5472-5481. Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. PMID: 34312215; PMCID: PMC8530870.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  44. Informed Consent: Is It Really? J Natl Compr Canc Netw. 2021 06 30; 19(6):665. Tempero M. PMID: 34214973.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  45. Open Notes Are Here: Are We Ready? J Natl Compr Canc Netw. 2021 05 01; 19(5):477. Tempero M. PMID: 34794123.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  46. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Nov; 28(12):7545-7554. Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. PMID: 33813673.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
  47. Being Closer to Normal. J Natl Compr Canc Netw. 2021 04 01; 19(4):363. Tempero M. PMID: 33845458.
    View in: PubMed   Mentions:    Fields:    
  48. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 04 01; 19(4):439-457. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. PMID: 33845462.
    View in: PubMed   Mentions: 409     Fields:    Translation:Humans
  49. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 08; 11(8):2014-2031. Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM. PMID: 33727309; PMCID: PMC8338775.
    View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
  50. It's All About Trust! J Natl Compr Canc Netw. 2021 03 02; 19(3):239. Tempero M. PMID: 33668022.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  51. Learning From Our Mistakes. J Natl Compr Canc Netw. 2021 02 02; 19(2):121. Tempero M. PMID: 33545686.
    View in: PubMed   Mentions:    Fields:    
  52. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 05; 32(5):600-608. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T. PMID: 33539945.
    View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
  53. New Year's Resolutions - A Different Perspective. J Natl Compr Canc Netw. 2021 01 06; 19(1):1. Tempero M. PMID: 33406497.
    View in: PubMed   Mentions:    Fields:    
  54. Lasting Effects of COVID-19: Reimbursement Reform? J Natl Compr Canc Netw. 2020 11 02; 18(11):1435. Tempero M. PMID: 33152702.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
  55. Flirting With Disaster: COVID-19 and Cancer. J Natl Compr Canc Netw. 2020 10 01; 18(10):1291. Tempero M. PMID: 33022645.
    View in: PubMed   Mentions:    Fields:    
  56. COVID-19 and Cancer: Unintended Consequences. J Natl Compr Canc Netw. 2020 09; 18(9):1147. Tempero M. PMID: 32886904.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
  57. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020 09 01; 130(9):4704-4709. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. PMID: 32749238; PMCID: PMC7456216.
    View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
  58. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 09 20; 38(27):3185-3194. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ, HALO 109-301 Investigators. PMID: 32706635; PMCID: PMC7499614.
    View in: PubMed   Mentions: 190     Fields:    Translation:HumansCTClinical Trials
  59. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol Ther. 2020 11 04; 28(11):2367-2378. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. PMID: 32730744; PMCID: PMC7647666.
    View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
  60. I Can't Breathe! J Natl Compr Canc Netw. 2020 07; 18(7):793. Tempero M. PMID: 32634769.
    View in: PubMed   Mentions:    Fields:    
  61. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020 09; 215(3):610-616. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. PMID: 32755156.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
  62. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clin Cancer Res. 2020 09 15; 26(18):4743-4747. Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM. PMID: 32571790.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  63. My Two-Dimensional Life. J Natl Compr Canc Netw. 2020 06; 18(6):649. Tempero M. PMID: 32502979.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCells
  64. Lessons From a Tiny Strand of RNA. J Natl Compr Canc Netw. 2020 05; 18(5):493. Tempero M. PMID: 32380459.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  65. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clin Cancer Res. 2020 07 15; 26(14):3578-3588. Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. PMID: 32273276; PMCID: PMC7727397.
    View in: PubMed   Mentions: 69     Fields:    Translation:HumansCellsCTClinical Trials
  66. Health and the Gut Microbiome: Who Knew? J Natl Compr Canc Netw. 2020 04; 18(4):365. Tempero M. PMID: 32259784.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  67. Taking Our Hands Off the Wheel. J Natl Compr Canc Netw. 2020 03; 18(3):221. Tempero M. PMID: 32135519.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  68. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas. 2020 03; 49(3):393-407. Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. PMID: 32132518; PMCID: PMC7077976.
    View in: PubMed   Mentions: 11     Fields:    Translation:Humans
  69. It's About Time! J Natl Compr Canc Netw. 2020 02; 18(2):115. Tempero M. PMID: 32023523.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  70. This Time I Mean It! J Natl Compr Canc Netw. 2020 01; 18(1):1. Tempero M. PMID: 31910382.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  71. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. PMID: 31634155.
    View in: PubMed   Mentions: 12     Fields:    Translation:Humans
  72. Santa, Can You Hear Me? J Natl Compr Canc Netw. 2019 12; 17(12):1455. Tempero M. PMID: 31805531.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  73. Giving Thanks. J Natl Compr Canc Netw. 2019 11 01; 17(11):1267. Tempero M. PMID: 31693979.
    View in: PubMed   Mentions:    Fields:    
  74. My Summer Vacation. J Natl Compr Canc Netw. 2019 10 01; 17(10):1147. Tempero M. PMID: 31590150.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  75. We All Own This! J Natl Compr Canc Netw. 2019 09 01; 17(9):1021. Tempero M. PMID: 31487675.
    View in: PubMed   Mentions:    Fields:    
  76. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 02 10; 38(5):496-520. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. PMID: 31381464.
    View in: PubMed   Mentions: 500     Fields:    Translation:Humans
  77. Managing Expectations. J Natl Compr Canc Netw. 2019 08 01; 17(8):893. Tempero M. PMID: 31390589.
    View in: PubMed   Mentions:    Fields:    
  78. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas. 2019 08; 48(7):927-930. Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. PMID: 31268983.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  79. Taking the Mountain to Muhammad. J Natl Compr Canc Netw. 2019 07 01; 17(7):767. Tempero M. PMID: 31319392.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  80. Tackling Cost: A Prescription for Spending Wisely. J Natl Compr Canc Netw. 2019 06 01; 17(6):633. Tempero M. PMID: 31200360.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  81. Finding Room for Success. J Natl Compr Canc Netw. 2019 05 01; 17(5):407. Tempero M. PMID: 31085761.
    View in: PubMed   Mentions:    Fields:    
  82. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019 05 01; 17(5.5):603-605. Tempero MA. PMID: 31117041.
    View in: PubMed   Mentions: 167     Fields:    Translation:Humans
  83. The Time Has Come! J Natl Compr Canc Netw. 2019 04 01; 17(4):295. Tempero M. PMID: 30959464.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  84. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 04; 18(2):241-251. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. PMID: 30267352.
    View in: PubMed   Mentions: 13     Fields:    Translation:Humans
  85. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019 03; 43(3):334-340. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. PMID: 30211728.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  86. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 03 01; 17(3):202-210. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. PMID: 30865919.
    View in: PubMed   Mentions: 169     Fields:    Translation:Humans
  87. Kids, There's an App for That! J Natl Compr Canc Netw. 2019 02; 17(2):101. Tempero M. PMID: 30787121.
    View in: PubMed   Mentions:    Fields:    
  88. New Year, New Look! J Natl Compr Canc Netw. 2019 01; 17(1):1. Tempero M. PMID: 30659122.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  89. An Oncologist's Letter to Santa: Bring Me Drugs! J Natl Compr Canc Netw. 2018 12; 16(12):1411. Tempero M. PMID: 30545986.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  90. I'm Conflicted. Are You? J Natl Compr Canc Netw. 2018 11; 16(11):1273. Tempero M. PMID: 30442729.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  91. One Size Fits All? Really? J Natl Compr Canc Netw. 2018 10; 16(10):1161. Tempero M. PMID: 30323084.
    View in: PubMed   Mentions: 2     Fields:    Translation:Humans
  92. Getting What You Pay For: Finding Value in Cancer Care. J Natl Compr Canc Netw. 2018 09; 16(9):1031. Tempero M. PMID: 30181413.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  93. Notes From the Other Side. J Natl Compr Canc Netw. 2018 08; 16(8):921-922. Tempero M. PMID: 30099366.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  94. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. PMID: 30063366.
    View in: PubMed   Mentions: 12     Fields:    Translation:Humans
  95. Genomic Medicine Takes the Stage, Again! J Natl Compr Canc Netw. 2018 07; 16(7):795. Tempero M. PMID: 30006420.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  96. Movin' On Up! J Natl Compr Canc Netw. 2018 06; 16(6):675. Tempero M. PMID: 29891517.
    View in: PubMed   Mentions:    Fields:    
  97. Getting Into the Weeds. J Natl Compr Canc Netw. 2018 05; 16(5):457. Tempero M. PMID: 29752317.
    View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
  98. Standing Together or Alone. J Natl Compr Canc Netw. 2018 Apr; 16(4):341. Tempero M. PMID: 29632051.
    View in: PubMed   Mentions:    Fields:    
  99. Molecular Diagnostics: Another Battle Brewing. J Natl Compr Canc Netw. 2018 Mar; 16(3):225. Tempero M. PMID: 29523658.
    View in: PubMed   Mentions:    Fields:    
  100. Extending Our Reach-Will Telemedicine Get Us There? J Natl Compr Canc Netw. 2018 Feb; 16(2):107. Tempero M. PMID: 29439170.
    View in: PubMed   Mentions:    Fields:    
  101. Revisiting New Year's Resolutions. J Natl Compr Canc Netw. 2018 01; 16(1):1. Tempero M. PMID: 29295874.
    View in: PubMed   Mentions:    Fields:    
  102. It's About Time! J Natl Compr Canc Netw. 2017 12; 15(12):1443. Tempero M. PMID: 29223979.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  103. Who's Watching the Kids? J Natl Compr Canc Netw. 2017 11; 15(11):1289. Tempero M. PMID: 29118220.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  104. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer J. 2017 Nov/Dec; 23(6):309. Tempero MA. PMID: 29189324.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  105. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. PMID: 29228650; PMCID: PMC5716690.
    View in: PubMed   Mentions: 18     Fields:    
  106. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018 Jan; 14(1):13-22. Doherty GJ, Tempero M, Corrie PG. PMID: 29235360.
    View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
  107. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. J Natl Compr Canc Netw. 2017 10; 15(10):1179. Tempero M. PMID: 28982741.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  108. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 12; 22(12):1427-e129. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. PMID: 28935773; PMCID: PMC5728028.
    View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
  109. Your Genes: Getting the Best Fit. J Natl Compr Canc Netw. 2017 09; 15(9):1083. Tempero M. PMID: 28874592.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  110. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 08; 15(8):1028-1061. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. PMID: 28784865.
    View in: PubMed   Mentions: 354     Fields:    Translation:Humans
  111. When It's Really Good, We Know It! J Natl Compr Canc Netw. 2017 08; 15(8):973. Tempero M. PMID: 28784856.
    View in: PubMed   Mentions:    Fields:    
  112. Reducing the Cost of Cancer Care: When Less Is More. J Natl Compr Canc Netw. 2017 07; 15(7):853. Tempero M. PMID: 28687571.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  113. Getting Practical About Recertification. J Natl Compr Canc Netw. 2017 06; 15(6):753. Tempero M. PMID: 28596253.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  114. Hospice: Angels at Work. J Natl Compr Canc Netw. 2017 05; 15(5):549. Tempero M. PMID: 28476733.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  115. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017 05; 15(5S):723-725. Tempero M. PMID: 28515255.
    View in: PubMed   Mentions: 2     Fields:    Translation:Humans
  116. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4). Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. PMID: 28376157; PMCID: PMC5441297.
    View in: PubMed   Mentions: 77     Fields:    Translation:Humans
  117. Politics as Usual-Not! J Natl Compr Canc Netw. 2017 04; 15(4):425. Tempero M. PMID: 28404753.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  118. Saying Yes. J Natl Compr Canc Netw. 2017 03; 15(3):277. Tempero M. PMID: 28275029.
    View in: PubMed   Mentions:    Fields:    
  119. Mad About MACRA. J Natl Compr Canc Netw. 2017 02; 15(2):137. Tempero M. PMID: 28188184.
    View in: PubMed   Mentions:    Fields:    
  120. New Year's Resolutions. J Natl Compr Canc Netw. 2017 01; 15(1):1. Tempero M. PMID: 28040714.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  121. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. PMID: 27929677; PMCID: PMC5749588.
    View in: PubMed   Mentions: 9     Fields:    Translation:Humans
  122. An Oncologist's Letter to Santa. J Natl Compr Canc Netw. 2016 12; 14(12):1491. Tempero M. PMID: 27956532.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  123. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 01; 152(1):68-74.e2. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV. PMID: 27856273.
    View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
  124. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 11; 45(10):1394-1400. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. PMID: 27171514.
    View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
  125. My Knee Hurts! J Natl Compr Canc Netw. 2016 11; 14(11):1335. Tempero M. PMID: 27799504.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  126. Crossing the Line. J Natl Compr Canc Netw. 2016 10; 14(10):1191. Tempero M. PMID: 27697973.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  127. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 09; 14(9):1047. Tempero M. PMID: 27587617.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  128. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 08; 14(8):929. Tempero M. PMID: 27496107.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCells
  129. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. PMID: 27444658.
    View in: PubMed   Mentions: 15     Fields:    Translation:Humans
  130. The Greatest Show on Earth! J Natl Compr Canc Netw. 2016 07; 14(7):813. Tempero M. PMID: 27407120.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  131. Did the IRB Approve This? J Natl Compr Canc Netw. 2016 06; 14(6):699. Tempero M. PMID: 27283161.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  132. Closely Guarded Secrets. J Natl Compr Canc Netw. 2016 05; 14(5):487. Tempero M. PMID: 27160226.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  133. Pancreatic cancer. Nat Rev Dis Primers. 2016 04 21; 2:16022. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. PMID: 27158978.
    View in: PubMed   Mentions: 810     Fields:    Translation:HumansAnimals
  134. Letting Nature Loose. J Natl Compr Canc Netw. 2016 Apr; 14(4):367. Tempero M. PMID: 27059185.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  135. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. PMID: 26390428; PMCID: PMC5908466.
    View in: PubMed   Mentions: 115     Fields:    Translation:HumansCellsCTClinical Trials
  136. Promising the Moon! J Natl Compr Canc Netw. 2016 Mar; 14(3):237. Tempero M. PMID: 26957609.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  137. Put Us Out of Business--Please! J Natl Compr Canc Netw. 2016 Feb; 14(2):123. Tempero M. PMID: 26850482.
    View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
  138. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. J Oncol Pract. 2016 Jan; 12(1):29-30. Tempero M. PMID: 26759462.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  139. Bringing Biosimilars to the Clinic: What's the Fuss? J Natl Compr Canc Netw. 2016 Jan; 14(1):1. Tempero M. PMID: 26733549.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  140. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016 Mar; 6(3):270-85. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. PMID: 26715645; PMCID: PMC4783268.
    View in: PubMed   Mentions: 271     Fields:    Translation:HumansAnimalsCells
  141. Paying Less for High-Value Care--Are You Kidding Me? J Natl Compr Canc Netw. 2015 Dec; 13(12):1453. Tempero M. PMID: 26656513.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  142. At Last: Getting Paid to Think! J Natl Compr Canc Netw. 2015 Nov; 13(11):1297. Tempero M. PMID: 26553759.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  143. Putting an End to It! J Natl Compr Canc Netw. 2015 Oct; 13(10):1167. Tempero M. PMID: 26483055.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  144. Crossing Over. J Natl Compr Canc Netw. 2015 Sep; 13(9):1053. Tempero M. PMID: 26358787.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  145. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290; PMCID: PMC4703532.
    View in: PubMed   Mentions: 57     Fields:    Translation:HumansCellsCTClinical Trials
  146. Move It! J Natl Compr Canc Netw. 2015 Aug; 13(8):939. Tempero M. PMID: 26285237.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  147. Express Scripts? Really? J Natl Compr Canc Netw. 2015 Jul; 13(7):827. Tempero M. PMID: 26150575.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  148. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333; PMCID: PMC4592417.
    View in: PubMed   Mentions: 138     Fields:    Translation:Humans
  149. Improving Access to Drugs--Big Pharma Comes to the Table. J Natl Compr Canc Netw. 2015 Jun; 13(6):703. Tempero M. PMID: 26085384.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  150. Multidisciplinary management of pancreatic cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):700-2. Tempero MA. PMID: 25995435.
    View in: PubMed   Mentions: 7     Fields:    Translation:Humans
  151. Reducing costs by changing behavior-really? J Natl Compr Canc Netw. 2015 May; 13(5):499. Tempero M. PMID: 25964633.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  152. Turf war over diagnostic testing. J Natl Compr Canc Netw. 2015 Apr; 13(4):375. Tempero M. PMID: 25870372.
    View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
  153. Putting precision medicine on the national agenda. J Natl Compr Canc Netw. 2015 Mar; 13(3):251. Tempero M. PMID: 25736000.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  154. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26; 518(7540):495-501. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. PMID: 25719666; PMCID: PMC4523082.
    View in: PubMed   Mentions: 1286     Fields:    Translation:HumansAnimalsCells
  155. All bundled up! J Natl Compr Canc Netw. 2015 Feb; 13(2):121. Tempero M. PMID: 25691601.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  156. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A, American Society of Clinical Oncology. PMID: 25605844; PMCID: PMC4881372.
    View in: PubMed   Mentions: 273     Fields:    Translation:Humans
  157. Meet the New JNCCN! J Natl Compr Canc Netw. 2015 Jan; 13(1):1. Tempero M. PMID: 25583762.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  158. Happy anniversary! J Natl Compr Canc Netw. 2014 Dec; 12(12):1653. Tempero M. PMID: 25505204.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  159. Bringing science to clinical practice. J Natl Compr Canc Netw. 2014 Nov; 12(11):1495. Tempero M. PMID: 25361794.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  160. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359. Tempero M. PMID: 25313175.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  161. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. PMID: 25199993; PMCID: PMC5554431.
    View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
  162. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199. Tempero M. PMID: 25190688.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  163. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069. Tempero M. PMID: 25099438.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  164. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. PMID: 25099441.
    View in: PubMed   Mentions: 130     Fields:    Translation:Humans
  165. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953. Tempero M. PMID: 24994914.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  166. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845. Tempero M. PMID: 24925194.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  167. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May; 12(5):603. Tempero M. PMID: 24812128.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  168. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. PMID: 24622062; PMCID: PMC3955845.
    View in: PubMed   Mentions: 5     Fields:    Translation:Humans
  169. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr; 12(4):449. Tempero M. PMID: 24717562.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  170. JNCCN going forward. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):301. Tempero M. PMID: 24616533.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  171. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191; PMCID: PMC3790192.
    View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
  172. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. PMID: 23880820; PMCID: PMC3749576.
    View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
  173. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. PMID: 23622141.
    View in: PubMed   Mentions: 142     Fields:    Translation:Humans
  174. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical Practice. PMID: 23669224.
    View in: PubMed   Mentions: 252     Fields:    Translation:Humans
  175. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 01; 19(3):538-40. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. PMID: 23344262.
    View in: PubMed   Mentions: 9     Fields:    Translation:Humans
  176. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64. Cinar P, Tempero MA. PMID: 23187854.
    View in: PubMed   Mentions: 9     Fields:    Translation:Humans
  177. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. PMID: 23103869; PMCID: PMC3530898.
    View in: PubMed   Mentions: 1100     Fields:    Translation:HumansAnimalsCells
  178. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
    View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
  179. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. PMID: 23053263.
    View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
  180. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks. PMID: 22679115; PMCID: PMC3807091.
    View in: PubMed   Mentions: 117     Fields:    Translation:Humans
  181. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. PMID: 21460848; PMCID: PMC3755490.
    View in: PubMed   Mentions: 899     Fields:    Translation:HumansAnimalsCells
  182. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jul; 22(7):1500-1506. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. PMID: 21199884.
    View in: PubMed   Mentions: 18     Fields:    Translation:Humans
  183. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5. Collisson E, Tempero M. PMID: 21106729.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  184. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma. PMID: 20876541; PMCID: PMC3135380.
    View in: PubMed   Mentions: 70     Fields:    
  185. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8. International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cros A, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BB, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbauer H, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, et al. PMID: 20393554; PMCID: PMC2902243.
    View in: PubMed   Mentions: 1155     Fields:    
  186. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
    View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
  187. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. PMID: 19858397; PMCID: PMC7587401.
    View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimals
  188. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. PMID: 19858396; PMCID: PMC2792952.
    View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
  189. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. Ko AH, Tempero MA. PMID: 19041649.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  190. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. PMID: 18815548.
    View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
  191. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol. 2008 Jun; 19 Suppl 6:vi1-8. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. PMID: 18539618.
    View in: PubMed   Mentions: 20     Fields:    Translation:Humans
  192. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. PMID: 18379729.
    View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
  193. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 18181045.
    View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
  194. How I treat pancreatic ductal adenocarcinoma. J Oncol Pract. 2008 Jan; 4(1):46-7. Tempero MA. PMID: 20859443; PMCID: PMC2793930.
    View in: PubMed   Mentions:    Fields:    
  195. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. PMID: 18053426.
    View in: PubMed   Mentions: 17     Fields:    Translation:Humans
  196. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007 Jun; 18 Suppl 7:vii1-vii10. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. PMID: 17600091.
    View in: PubMed   Mentions: 24     Fields:    Translation:Humans
  197. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. PMID: 17363191.
    View in: PubMed   Mentions: 34     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  198. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A, Workshop Program Committee. PMID: 17655039.
    View in: PubMed   Mentions: 7     Fields:    Translation:Humans
  199. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. PMID: 16957834.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
  200. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 01; 66(1):14-7. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. PMID: 16397208.
    View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
  201. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 16344320.
    View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
  202. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. Ko AH, Tempero MA. PMID: 16183478.
    View in: PubMed   Mentions: 3     Fields:    Translation:Humans
  203. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626. Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA, National Comprehensive Cancer Network. PMID: 16194453.
    View in: PubMed   Mentions: 10     Fields:    Translation:Humans
  204. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. Ko AH, Tempero MA. PMID: 16194454.
    View in: PubMed   Mentions: 5     Fields:    Translation:Humans
  205. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. PMID: 15999098; PMCID: PMC2361548.
    View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
  206. Clinical oncology 2004: the president's report. J Clin Oncol. 2004 Nov 15; 22(22):4437-41. Tempero MA. PMID: 15542796.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  207. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. PMID: 12885837.
    View in: PubMed   Mentions: 121     Fields:    Translation:HumansCTClinical Trials
  208. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. PMID: 15361643.
    View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
  209. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep; 2(8):774-9. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. PMID: 12243499.
    View in: PubMed   Mentions: 79     Fields:    Translation:Humans
  210. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002 Jul; 43(7):957-67. Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. PMID: 12097469.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
  211. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. Ko AH, Tempero MA. PMID: 11937010.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  212. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash). 2002 Jan-Feb; 42(1):93-100. Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA. PMID: 11833524.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  213. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001 Jun 15; 61(12):4923-32. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. PMID: 11406572.
    View in: PubMed   Mentions: 34     Fields:    Translation:Humans
  214. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001 Jun; 42(6):907-15. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, Vose JM. PMID: 11390555.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
  215. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol. 2001 May 01; 19(9):2404-12. Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. PMID: 11331319.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
  216. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res. 2001 Jan; 7(1):175-84. Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK. PMID: 11205906.
    View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
  217. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000 Aug; 6(8):3095-102. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. PMID: 10955789.
    View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
  218. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Jun; 38(1-2):91-101. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO. PMID: 10811451.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
  219. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000 Feb; 6(2):406-14. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. PMID: 10690517.
    View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
  220. Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. Cancer Chemother Pharmacol. 2000; 45(3):247-51. Gwilt P, Tempero M, Kremer A, Connolly M, Ding C. PMID: 10663643.
    View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
  221. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999 Dec; 117(6):1464-84. DiMagno EP, Reber HA, Tempero MA. PMID: 10579989.
    View in: PubMed   Mentions: 107     Fields:    Translation:Humans
  222. Pancreatic cancer. Curr Opin Oncol. 1998 Jul; 10(4):362-6. Brand RE, Tempero MA. PMID: 9702405.
    View in: PubMed   Mentions: 14     Fields:    Translation:Humans
  223. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998 May 01; 82(9):1800-1. Tempero MA, Brand R. PMID: 9576306.
    View in: PubMed   Mentions: 4     Fields:    Translation:Humans
  224. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. J Vasc Interv Radiol. 1998 Mar-Apr; 9(2):233-9. Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. PMID: 9540905.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  225. Biologic therapy of gastrointestinal cancer. Cancer Treat Res. 1998; 98:227-37. Tempero M. PMID: 10326671.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  226. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997 Apr; 15(4):1518-28. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D. PMID: 9193348.
    View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
  227. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997 Apr; 38(4):512-6. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. PMID: 9098192.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
  228. Walking a difficult path is easier with a friend. Thoughts from a practicing oncologist. Ann N Y Acad Sci. 1997 Feb 20; 809:237-42. Tempero MA. PMID: 9103574.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  229. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997; 15(4):331-41. Brand R, Capadano M, Tempero M. PMID: 9547676.
    View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
  230. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol. 1997 Jan; 17(1):96-106. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D. PMID: 9049790.
    View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
  231. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):140-75. Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, Tempero M. PMID: 8953601.
    View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
  232. Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochim Biophys Acta. 1996 Oct 07; 1317(1):65-70. Haga Y, Tempero MA, Zetterman RK. PMID: 8876628.
    View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
  233. Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes. Dig Dis Sci. 1996 Jul; 41(7):1468-74. Haga Y, Tempero MA, Kay D, Zetterman RK. PMID: 8689926.
    View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
  234. Unconjugated bilirubin inhibits in vitro major histocompatibility complex-unrestricted cytotoxicity of human lymphocytes. Biochim Biophys Acta. 1996 May 24; 1316(1):29-34. Haga Y, Tempero MA, Zetterman RK. PMID: 8634340.
    View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
  235. Radiolabeled iododeoxyuridine: safety evaluation. J Nucl Med. 1996 Apr; 37(4 Suppl):13S-16S. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. PMID: 8676196.
    View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
  236. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):156-65. Sivinski CL, Lindner DJ, Borden EC, Tempero MA. PMID: 8770771.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
  237. New imaging techniques in colorectal cancer. Semin Oncol. 1995 Oct; 22(5):448-71. Tempero M, Brand R, Holdeman K, Matamoros A. PMID: 7570057.
    View in: PubMed   Mentions: 4     Fields:    Translation:Humans
  238. Diagnostic use of radiolabeled antibodies for cancer. Oncology (Williston Park). 1995 Jul; 9(7):625-31 DISC 634, 636, 641. Harrison KA, Tempero MA. PMID: 8924373.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  239. Malignancies after liver transplantation: a comparative review. Semin Liver Dis. 1995 May; 15(2):156-64. Tan-Shalaby J, Tempero M. PMID: 7660168.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  240. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization. J Hematother. 1995 Apr; 4(2):81-4. Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. PMID: 7543352.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
  241. Immunologic effects of levamisole in mice and humans: evidence for augmented antibody response without modulation of cellular cytotoxicity. J Immunother Emphasis Tumor Immunol. 1995 Jan; 17(1):47-57. Tempero MA, Haga Y, Sivinski C, Birt D, Klassen L, Thiele G. PMID: 7728305.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
  242. Hypersensitivity to therapeutic murine monoclonal antibodies. Nebr Med J. 1994 Dec; 79(12):393-8. Kornbrot B, Kobayashi RH, Singer A, Tempero MA, Heiner DC. PMID: 7870212.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
  243. Progress in colon cancer: do molecular markers matter? N Engl J Med. 1994 Jul 28; 331(4):267-8. Tempero M, Anderson J. PMID: 8015575.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  244. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev. 1994 Mar; 3(2):155-60. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. PMID: 8049637.
    View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
  245. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int J Pancreatol. 1994 Feb; 15(1):43-50. Haga Y, Sivinski CL, Woo D, Tempero MA. PMID: 8195641.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
  246. Cancer therapy using radioimmunoconjugates. Implications for breast cancer. Ann N Y Acad Sci. 1993 Nov 30; 698:406-17. Tempero M, Colcher D, Dalrymple G, Harrison K, Holdeman K, Joshi S, Quadri S, Linder J, Augustine S, Reed E, et al. PMID: 8279780.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  247. Pitfalls in antibody imaging in colorectal cancer. Cancer. 1993 Jun 15; 71(12 Suppl):4248-51. Tempero M. PMID: 8508387.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  248. Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. Carcinogenesis. 1992 Oct; 13(10):1829-33. Hirota M, Pour PM, Tempero MA, Chaney WG. PMID: 1385001.
    View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
  249. Flow cytometric measurement of intracellular bilirubin in human peripheral blood mononuclear cells exposed to unconjugated bilirubin. Clin Biochem. 1992 Aug; 25(4):277-83. Haga Y, Kay HD, Tempero MA, Zetterman RK. PMID: 1381998.
    View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
  250. Characterization of bilirubin transport system by human peripheral blood mononuclear cells. J Leukoc Biol. 1992 Jan; 51(1):2-6. Haga Y, Tempero MA, Kay HD, Zetterman RK. PMID: 1740642.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  251. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments. Tumour Biol. 1992; 13(4):195-206. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. PMID: 1411138.
    View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
  252. Progress in chemoprevention of gastrointestinal cancers. Curr Opin Oncol. 1991 Aug; 3(4):719-26. Tempero MA. PMID: 1834193.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  253. Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. Am J Pathol. 1991 Mar; 138(3):557-61. Egami H, Tomioka T, Tempero M, Kay D, Pour PM. PMID: 2000935; PMCID: PMC1886266.
    View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
  254. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. Int J Pancreatol. 1991; 9:125-34. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. PMID: 1744438.
    View in: PubMed   Mentions: 2     Fields:    Translation:Humans
  255. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol. 1990 Dec; 8(12):2019-26. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD. PMID: 2121912.
    View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
  256. Advances in the medical management of advanced gastrointestinal cancers. Curr Opin Oncol. 1990 Aug; 2(4):747-53. Tempero MA. PMID: 2095882.
    View in: PubMed   Mentions:    Fields:    
  257. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res. 1989 Nov 01; 49(21):5793-7. Tempero MA, Nishioka K, Knott K, Zetterman RK. PMID: 2507137.
    View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
  258. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol. 1989 Sep; 20(9):832-8. Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM. PMID: 2673979.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  259. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A. Proc Natl Acad Sci U S A. 1989 May; 86(10):3787-91. Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D. PMID: 2786203; PMCID: PMC287225.
    View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
  260. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. Am J Surg Pathol. 1989; 13 Suppl 1:89-95. Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS, Pour PM. PMID: 2699170.
    View in: PubMed   Mentions: 4     Fields:    Translation:Humans
  261. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer. 1988 Nov 15; 42(5):681-6. Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. PMID: 3053465.
    View in: PubMed   Mentions: 9     Fields:    Translation:Humans
  262. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 01; 48(19):5422-6. Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. PMID: 3166398.
    View in: PubMed   Mentions: 47     Fields:    Translation:Humans
  263. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Mod Pathol. 1988 Jul; 1(4):279-83. Ness MJ, Pour PM, Tempero MA, Linder J. PMID: 2467286.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  264. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988 Mar 15; 48(6):1435-8. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. PMID: 3162196.
    View in: PubMed   Mentions: 27     Fields:    Translation:Humans
  265. Relationship of dietary cholesterol and cellulose in the prevention of colon cancer. Cancer Detect Prev. 1988; 13(1):41-54. Tempero MA, Knott KK, Zetterman RK. PMID: 3224345.
    View in: PubMed   Mentions:    Fields:    Translation:Animals
  266. Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment. J Surg Oncol. 1987 Dec; 36(4):253-8. Tempero MA, Zetterman RK. PMID: 3695530.
    View in: PubMed   Mentions: 1     Fields:    Translation:Animals
  267. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15; 47(20):5501-3. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. PMID: 3308077.
    View in: PubMed   Mentions: 151     Fields:    Translation:Humans
  268. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue. Int J Pancreatol. 1987 Oct-Dec; 2(5-6):349-60. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. PMID: 3320227.
    View in: PubMed   Mentions: 3     Fields:    Translation:Humans
  269. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl. 1987; 1:145-8. Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. PMID: 3319143.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  270. In vitro regulation of human lymphocyte proliferation by selenium. Biol Trace Elem Res. 1986 Dec; 11(1):129-46. Petrie HT, Klassen LW, Tempero MA, Kay HD. PMID: 24254509.
    View in: PubMed   Mentions: 3     Fields:    
  271. The effect of selenium on cell proliferation in liver and colon. Biol Trace Elem Res. 1986 Aug; 10(2):145-52. Tempero MA, Deschner EE, Zedeck MS. PMID: 24254361.
    View in: PubMed   Mentions: 2     Fields:    
  272. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. J Clin Oncol. 1986 Jul; 4(7):1074-8. Tempero MA, Williams CA, Anderson JC. PMID: 3522817.
    View in: PubMed   Mentions: 5     Fields:    Translation:Humans
  273. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma. 1986 Jul; 5 Suppl 1:S51-8. Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H. PMID: 3488951.
    View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
  274. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986 Jul; 5 Suppl 1:S133-8. Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. PMID: 3744378.
    View in: PubMed   Mentions: 11     Fields:    Translation:Humans
  275. The importance of luminal factors in neomucosal growth. J Surg Res. 1986 Feb; 40(2):126-32. Thompson JS, Tempero MA, Haun JL, Vanderhoof JA. PMID: 3945070.
    View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
  276. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig Dis. 1986; 4(1):49-56. Tempero M. PMID: 3545561.
    View in: PubMed   Mentions: 3     Fields:    Translation:Humans
  277. The undifferentiated malignant neoplasm. Identification of lymphoma arising in skeletal muscle by immunohistochemical analysis. JAMA. 1985 Nov 08; 254(18):2625-6. Berg AR, Linder J, Anderson RW, Tempero MA, Edney JA, Armitage JO. PMID: 2414476.
    View in: PubMed   Mentions: 3     Fields:    Translation:Humans
  278. Thrombocytopenia and laboratory evidence of disseminated intravascular coagulation after shunts for ascites in malignant disease. Cancer. 1985 Jun 01; 55(11):2718-21. Tempero MA, Davis RB, Reed E, Edney J. PMID: 3995480.
    View in: PubMed   Mentions: 3     Fields:    Translation:Humans
  279. Serum and hair selenium levels in hereditary nonpolyposis colorectal cancer. Biol Trace Elem Res. 1984 Feb; 6(1):51-5. Tempero MA, Jacobs MM, Lynch HT, Graham CL, Blotcky AJ. PMID: 24263746.
    View in: PubMed   Mentions: 1     Fields:    
  280. Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. J Surg Oncol. 1982 Nov; 21(3):159-61. Tempero MA, Kessinger A. PMID: 6813600.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  281. Detection of metastatic liver disease. Use of liver scans and biochemical liver tests. JAMA. 1982 Sep 17; 248(11):1329-32. Tempero MA, Petersen RJ, Zetterman RK, Lemon HM, Gurney J. PMID: 7109154.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  282. Disseminated Mycobacterium kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia. Med Pediatr Oncol. 1981; 9(3):283-8. Tempero MA, Smith PW. PMID: 7242466.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  283. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. Cancer Clin Trials. 1981; 4(2):155-7. Tempero M, Kessinger A, Lemon HM. PMID: 6265110.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
Margaret's Networks
Concepts (656)
Derived automatically from this person's publications.
_
Co-Authors (73)
People in Profiles who have published with this person.
_
Similar People (60)
People who share similar concepts with this person.
_
Same Department
Search Department
_